The Food and Drug Administration failed to adhere to its own internal practices during the approval process for the Biogen Alzheimer’s drug Aduhelm, a new report states.
The Food and Drug Administration failed to adhere to its own internal practices during the approval process for the Biogen Alzheimer’s drug Aduhelm, a new report states.
This website, like most media sites, uses small files called cookies to anonymously customize the advertising that you see. Learn more about how we use cookies in our cookie policy.
